Compare FGII & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGII | TENX |
|---|---|---|
| Founded | 2025 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.5M | 317.8M |
| IPO Year | 2026 | 2001 |
| Metric | FGII | TENX |
|---|---|---|
| Price | $9.94 | $12.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 14.3K | ★ 629.9K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.86 | $5.34 |
| 52 Week High | $9.94 | $18.38 |
| Indicator | FGII | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 44.63 |
| Support Level | N/A | $10.83 |
| Resistance Level | N/A | $14.15 |
| Average True Range (ATR) | 0.01 | 0.73 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 100.00 | 48.36 |
FG Imperii Acquisition Corp is a blank check company incorporated in the Cayman Islands. The company was formed for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.